Spadin-derived heptapeptide studied as a TREK-1 channel blocker.
Also known as: Spadin analog
Part of the Neuropeptides & signaling cluster
Overview
PE-22-28 is a synthetic heptapeptide derived from spadin, developed as a shortened analog that inhibits the TREK-1 potassium channel. It has been examined in rodent neuroscience studies and is not authorized as a medicine by Health Canada.
Source & context
Biological / chemical source: Synthetic shortened analog of spadin
Primary research or clinical context: Preclinical research compound (not authorized by Health Canada)
From spadin to a shorter analog
Spadin is a natural peptide fragment from the propeptide of sortilin that blocks TREK-1 channels. PE-22-28 was engineered as a shortened, more stable analog, exemplifying how sequence trimming can change potency and in vivo half-life.
Research status
Reported effects come from preclinical rodent models involving TREK-1 pharmacology and hippocampal signaling. No completed human efficacy trials are published, and this page provides no dosing or medical guidance.
FAQ about PE-22-28
What is PE-22-28?+
PE-22-28 is a synthetic heptapeptide derived from spadin, developed as a shortened analog that inhibits the TREK-1 potassium channel. It has been examined in rodent neuroscience studies and is not authorized as a medicine by Health Canada.
Is PE-22-28 an approved medicine?+
PE-22-28 is discussed here as a research / educational topic. Preclinical research compound (not authorized by Health Canada). This is not medical advice.
What is the typical length of PE-22-28?+
PE-22-28 is commonly described as approximately 7 amino acids (Research peptide).